|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Rossi A, Maione P, Sacco PC, Sgambato A,
Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F and Gridelli C:
ALK inhibitors and advanced non-small cell lung cancer (Review).
Int J Oncol. 45:499–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raitoharju E, Seppala I, Oksala N,
Lyytikainen LP, Raitakari O, Viikari J, Ala-Korpela M, Soininen P,
Kangas AJ, Waldenberger M, et al: Blood microRNA profile associates
with the levels of serum lipids and metabolites associated with
glucose metabolism and insulin resistance and pinpoints pathways
underlying metabolic syndrome: The cardiovascular risk in young
finns study. Mol Cell Endocrinol. 391:41–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang F, Yu Q, Chu Y, Zhu X, Lu W, Liu Q
and Wang Q: MicroRNA-98-5p inhibits proliferation and metastasis in
non-small cell lung cancer by targeting TGFBR1. Int J Oncol.
54:128–138. 2019.
|
|
6
|
Tang Q, Li M, Chen L, Bi F and Xia H:
miR-200b/c targets the expression of RhoE and inhibits the
proliferation and invasion of non-small cell lung cancer cells. Int
J Oncol. 53:1732–1742. 2018.PubMed/NCBI
|
|
7
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Othman N and Nagoor NH: Overexpression of
miR-361-5p plays an oncogenic role in human lung adenocarcinoma
through the regulation of SMAD2. Int J Oncol. 54:306–314. 2019.
|
|
9
|
Rongxin S, Pengfei L, Li S, Xiaochen J and
Yihe H: MicroRNA-340-5p suppresses osteosarcoma development by
down-regulating the Wnt/β-catenin signaling pathway via targeting
the STAT3 gene. Eur Rev Med Pharmacol Sci. 23:982–991.
2019.PubMed/NCBI
|
|
10
|
Shi Z, Li Y, Qian X, Hu Y, Liu J, Zhang S
and Zhang J: miR-340 inhibits triple-negative breast cancer
progression by reversing EZH2 mediated miRNAs dysregulated
expressions. J Cancer. 8:3037–3048. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei P, Qiao B, Li Q, Han X, Zhang H, Huo Q
and Sun J: microRNA-340 suppresses tumorigenic potential of
prostate cancer cells by targeting high-mobility group
nucleosome-binding domain 5. DNA Cell Biol. 35:33–43. 2016.
View Article : Google Scholar
|
|
12
|
Huang D, Qiu S, Ge R, He L, Li M, Li Y and
Peng Y: miR-340 suppresses glioblastoma multiforme. Oncotarget.
6:9257–9270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang T, Zhou Y, Zhang J, Wong CC, Li W,
Kwan JSH, Yang R, Chan AKY, Dong Y, Wu F, et al: SRGAP1, a crucial
target of miR-340 and miR-124, functions as a potential oncogene in
gastric tumorigenesis. Oncogene. 37:1159–1174. 2018. View Article : Google Scholar :
|
|
14
|
Xie L, Chen Z, Liu H, Guan L, Wang Z and
Li W: Effects of miR-340 on hepatocellular carcinoma by targeting
the DcR3 gene. Dig Liver Dis. 50:291–296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao P, Ma W, Hu Z, Zhang Y, Zhang S and
Wang Y: Up-regulation of miR-340-5p promotes progression of thyroid
cancer by inhibiting BMP4. J Endocrinol Invest. 41:1165–1172. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen CP, Sun ZL, Lu X, Wu WX, Guo WL, Lu
JJ, Han C, Huang JQ and Fang Y: miR-340 suppresses cell migration
and invasion by targeting MYO10 in breast cancer. Oncol Rep.
35:709–716. 2016. View Article : Google Scholar
|
|
17
|
Mohammadi-Yeganeh S, Paryan M, Arefian E,
Vasei M, Ghanbarian H, Mahdian R, Karimipoor M and Soleimani M:
MicroRNA-340 inhibits the migration, invasion, and metastasis of
breast cancer cells by targeting Wnt pathway. Tumour Biol.
37:8993–9000. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maskey N, Li D, Xu H, Song H, Wu C, Hua K,
Song J and Fang L: MicroRNA-340 inhibits invasion and metastasis by
down-regulating ROCK1 in breast cancer cells. Oncol Lett.
14:2261–2267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Wang Y, Zhang W, Li J, Liu W and
Lu W: Long non-coding RNA SNHG14 exerts oncogenic functions in
non-small cell lung cancer through acting as a miR-340 sponge.
Biosci Rep. 39:pii: BSR20180941. 2019.
|
|
20
|
Qin Y, Zhou X, Huang C, Li L, Liu H, Liang
N, Chen Y, Ma D, Han Z, Xu X, et al: Lower miR-340 expression
predicts poor prognosis of non-small cell lung cancer and promotes
cell proliferation by targeting CDK4. Gene. 675:278–284. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar
|
|
22
|
Chia WJ and Tang BL: Emerging roles for
Rab family GTPases in human cancer. Biochim Biophys Acta.
1795:110–116. 2009.PubMed/NCBI
|
|
23
|
Bobrie A, Krumeich S, Reyal F, Recchi C,
Moita LF, Seabra MC, Ostrowski M and Théry C: Rab27a supports
exosome-dependent and -independent mechanisms that modify the
tumour microenvironment and can promote tumour progression. Cancer
Res. 72:4920–4930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong K, Chen K, Han L and Li B:
MicroRNA-30b/c inhibits non-small cell lung cancer cell
proliferation by targeting Rab18. BMC Cancer. 14:7032014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li W, Mu D, Tian F, Hu Y, Jiang T, Han Y,
Chen J, Han G and Li X: Exosomes derived from Rab27a-overexpressing
tumor cells elicit efficient induction of antitumor immunity. Mol
Med Rep. 8:1876–1882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Rezaei Z, Sebzari A, Kordi-Tamandani DM
and Dastjerdi K: Involvement of the dysregulation of miR-23b-3p,
miR-195-5p, miR-656-5p and miR-340-5p in trastuzumab resistance of
HER2-positive breast cancer cells and system biology approach to
predict their targets involved in resistance. DNA Cell Biol.
38:184–192. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J,
Zhao JJ, Mao SS, Zhang GH, Xu XC and Zhang N: miR-340 inhibition of
breast cancer cell migration and invasion through targeting of
oncoprotein c-Met. Cancer. 117:2842–2852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou LK, Yu Y, Xie YG, Wang J, Mao JF,
Zhang B, Wang X and Cao XC: miR-340 and ZEB1 negative feedback loop
regulates TGF-β-mediated breast cancer progression. Oncotarget.
7:26016–26026. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Gong X, Chen J, Zhang J, Sun J and
Guo M: miR-340 inhibits glioblastoma cell proliferation by
suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res
Commun. 460:670–677. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yamashita D, Kondo T, Ohue S, Takahashi H,
Ishikawa M, Matoba R, Suehiro S, Kohno S, Harada H, Tanaka J and
Ohnishi T: miR340 suppresses the stem-like cell function of
glioma-initiating cells by targeting tissue plasminogen activator.
Cancer Res. 75:1123–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeyama H, Yamamoto H, Yamashita S, Wu X,
Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata
K, et al: Decreased miR-340 expression in bone marrow is associated
with liver metastasis of colorectal cancer. Mol Cancer Ther.
13:976–985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li P, Sun Y and Liu Q: MicroRNA-340
induces apoptosis and inhibits metastasis of ovarian cancer cells
by inactivation of NF-x03BA;B1. Cell Physiol Biochem. 38:1915–1927.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang K, Tang Y, He L and Dai Y:
MicroRNA-340 inhibits prostate cancer cell proliferation and
metastasis by targeting the MDM2-p53 pathway. Oncol Rep.
35:887–895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu W, Zhang G, Lu B, Li J, Wu Z, Ma H,
Wang H and Lian R: miR-340 impedes the progression of laryngeal
squamous cell carcinoma by targeting EZH2. Gene. 577:193–201. 2016.
View Article : Google Scholar
|
|
36
|
Zhou X, Wei M and Wang W: MicroRNA-340
suppresses osteosarcoma tumor growth and metastasis by directly
targeting ROCK1. Biochem Biophys Res Commun. 437:653–658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin G, Zhou H, Xue Y, Yao B and Zhao W:
MicroRNA-340 promotes the tumor growth of human gastric cancer by
inhibiting cyclin G2. Oncol Rep. 36:1111–1118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Wang H, Ni Q, Tang Z, Ni J, Xu L,
Huang H, Ni S and Feng J: Effects of silencing Rab27a gene on
biological characteristics and chemosensitivity of non-small cell
lung cancer. Oncotarget. 8:94481–94492. 2017.PubMed/NCBI
|
|
39
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dong Q, Fu L, Zhao Y, Du Y, Li Q, Qiu X
and Wang E: Rab11a promotes proliferation and invasion through
regulation of YAP in non-small cell lung cancer. Oncotarget.
8:27800–27811. 2017.PubMed/NCBI
|
|
41
|
Imai A, Yoshie S, Ishibashi K,
Haga-Tsujimura M, Nashida T, Shimomura H and Fukuda M: EPI64 pr
parotid acinar cells otein functions as a physiological
GTPase-activating protein for RAB27 protein and regulates amylase
release in rat. J Biol Chem. 286:33854–33862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Akavia UD, Litvin O, Kim J, Sanchez-Garcia
F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA and
Pe'er D: An integrated approach to uncover drivers of cancer. Cell.
143:1005–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Peinado H, Alečković M, Lavotshkin S,
Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M,
Williams C, García-Santos G, Ghajar C, et al: Melanoma exosomes
educate bone marrow progenitor cells toward a pro-metastatic
phenotype through MET. Nat Med. 18:883–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Feng F, Jiang Y, Lu H, Lu X, Wang S, Wang
L, Wei M, Lu W, Du Z, Ye Z, et al: Rab27A mediated by NF-κB
promotes the stemness of colon cancer cells via up-regulation of
cytokine secretion. Oncotarget. 7:63342–63351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang H, Zhao Y, Zhang C, Li M, Jiang C and
Li Y: Rab27a was identified as a prognostic biomaker by mRNA
profiling, correlated with malignant progression and subtype
preference in gliomas. PLoS One. 9:e897822014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi C, Yang X, Ni Y, Hou N, Xu L, Zhan F,
Zhu H, Xiong L and Chen P: High RAB27A expression indicates
favorable prognosis in CRC. Diagn Pathol. 10:682015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hendrix A, Maynard D, Pauwels P, Braems G,
Denys H, Van den Broecke R, Lambert J, Van Belle S, Cocquyt V,
Gespach C, et al: Effect of the secretory small GTPase RAB27B on
breast cancer growth, invasion, and metastasis. J Natl Cancer Inst.
102:866–880. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Worst TS, Meyer Y, Gottschalt M, Weis CA,
von Hardenberg J, Frank C, Steidler A, Michel MS and Erben P:
RAB27A, RAB27B and VPS36 are downregulated in advanced prostate
cancer and show functional relevance in prostate cancer cells. Int
J Oncol. 50:920–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang X, Ye X, Sun L, Gao F, Li Y, Ji X and
Wang X, Feng Y and Wang X: Downregulation of serum RAB27B confers
improved prognosis and is associated with hepatocellular carcinoma
progression through PI3K-AKT-P21 signaling. Oncotarget.
8:61118–61132. 2017.PubMed/NCBI
|
|
50
|
Bao J, Ni Y, Qin H, Xu L, Ge Z, Zhan F,
Zhu H, Zhao J, Zhou X, Tang X and Tang L: Rab27b is a potential
predictor for metastasis and prognosis in colorectal cancer.
Gastroenterol Res Pract. 2014:9131062014. View Article : Google Scholar
|
|
51
|
Hendrix A, Braems G, Bracke M, Seabra M,
Gahl W, De Wever O and Westbroek W: The secretory small GTPase
Rab27B as a marker for breast cancer progression. Oncotarget.
1:304–308. 2010.
|
|
52
|
Koh HM and Song DH: Prognostic role of
Rab27A and Rab27B expression in patients with non-small cell lung
carcinoma. Thorac Cancer. 10:143–149. 2019. View Article : Google Scholar
|
|
53
|
Zhang L, Fan W, Xu L, Mao Q, Chen Y, Mao
Y, Xu L and Wang J: Rab27b is a potential indicator for lymph node
metastasis and unfavorable prognosis in lung adenocarcinoma. Dis
Markers. 2018:72939622018. View Article : Google Scholar
|
